Wire · regulatory
FDA Seeks Public Input to Advance Development of Botanical Drug Products
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
The FDA has issued a request for information to gather public input on advancing the development of botanical drug products, aiming to enhance regulatory pathways and scientific development while maintaining safety standards. This initiative includes a public comment period and plans for collaboration with the European Medicines Agency to discuss regulatory considerations.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a narrowing path to market for botanical drugs as the FDA signals increased scrutiny but also a structured dialogue to ease development. Engage now with the public comment to shape rules before they harden.
◆ Coverage
1 source · 3 Sep 2026
◆ Related on Wire
◆ Topics